National Toxicology Program (NTP); NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); Federal Agency Responses to Interagency Coordinating Committee on the Validation of Alternative Methods Recommendations on the Murine Local Lymph Node Assay, An Alternative Test Method for Assessing the Allergic Contact Dermatitis Potential of Chemicals and Products: Notice of Availability, 25866-25867 [2010-10954]
Download as PDF
25866
Federal Register / Vol. 75, No. 89 / Monday, May 10, 2010 / Notices
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact: David
Sharlip, National Library of Medicine,
Building 38A, Room B2N12, 8600
Rockville Pike, Bethesda, MD 20894, or
call non-toll free number 301–402–9680
or e-mail your request to
sharlipd@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
Dated: April 30, 2010.
Betsy L. Humphreys,
Deputy Director, National Library of
Medicine, National Institutes of Health.
[FR Doc. 2010–10950 Filed 5–7–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Title: Community Services Block
Grant (CSBG) Program Model Plan
Application.
OMB No.: New Collection.
Description: Sections 676 and 677 of
the Community Services Block Grant
Act require States, including the District
of Columbia and the Commonwealth of
Puerto Rico, Tribes, Tribal organizations
and U.S. territories applying for
Community Services Block Grant
(CSBG) funds to submit an application
and plan (Model Application Plan). The
application plan must meet statutory
requirements prior to being funded with
CSBG funds. Applicants have the option
to submit a detailed application
annually or biannually. Entities that
submit a biannual application must
provide an abbreviated application the
following year if substantial changes to
the initial application will occur. OMB
approval is being sought.
Respondents: State Governments,
including the District of Columbia and
the Commonwealth of Puerto Rico,
Tribal Governments, Tribal
Organizations, and U.S. territories.
ANNUAL BURDEN ESTIMATES
Number of
respondents
Instrument
jlentini on DSKJ8SOYB1PROD with NOTICES
Model State CSBG Application .......................................................................
Model Indian Tribes & Tribal Organizations CSBG Application ......................
Estimated Total Annual Burden
Hours: 860
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Administration, Office of Information
Services, 370 L’Enfant Promenade, SW.,
Washington, DC 20447, Attn: ACF
Reports Clearance Officer. All requests
should be identified by the title of the
information collection. E-mail address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Fax: 202–395–7285,
E-mail:
OIRA_SUBMISSION@OMB.EOP.GOV,
Attn: Desk Officer for the
Administration for Children and
Families.
Dated: May 4, 2010.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2010–10933 Filed 5–7–10; 8:45 am]
BILLING CODE 4184–01–P
VerDate Mar<15>2010
17:18 May 07, 2010
Jkt 220001
56
30
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Toxicology Program (NTP);
NTP Interagency Center for the
Evaluation of Alternative Toxicological
Methods (NICEATM); Federal Agency
Responses to Interagency
Coordinating Committee on the
Validation of Alternative Methods
Recommendations on the Murine Local
Lymph Node Assay, An Alternative
Test Method for Assessing the Allergic
Contact Dermatitis Potential of
Chemicals and Products: Notice of
Availability
AGENCY: National Institute of
Environmental Health Sciences
(NIEHS), National Institutes of Health
(NIH).
ACTION: Notice of Availability.
SUMMARY: U.S. Federal agency responses
to Interagency Coordinating Committee
on the Validation of Alternative
Methods (ICCVAM) test method
recommendations on the murine local
lymph node assay (LLNA), an
alternative safety testing method used to
assess the potential of chemicals and
products to cause allergic contact
dermatitis (ACD), are now available.
ICCVAM recommended an updated
LLNA test method protocol, a reduced
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1
1
Average
burden hours
per response
Total burden
hours
10
10
560
300
LLNA procedure (rLLNA), and LLNA
test method performance standards. In
accordance with the ICCVAM
Authorization Act, ICCVAM previously
forwarded recommendations to Federal
agencies and made these
recommendations available to the
public (74 FR 50212). Agencies have
now notified ICCVAM in writing of
their findings and ICCVAM is making
these responses available to the public.
Federal agency responses are available
on the NICEATM–ICCVAM Web site at
https://iccvam.niehs.nih.gov/methods/
immunotox/rLLNA.htm and https://
iccvam.niehs.nih.gov/methods/
immunotox/llna_PerfStds.htm. The
ICCVAM recommendations are
provided in ICCVAM Test Method
Evaluation Reports, which are available
on the NICEATM–ICCVAM Web site at
https://iccvam.niehs.nih.gov/methods/
immunotox/LLNA–LD/TMER.htm and
https://iccvam.niehs.nih.gov/methods/
immunotox/PerfStds/llna-ps.htm.
FOR FURTHER INFORMATION CONTACT: Dr.
William S. Stokes, Director, NICEATM,
NIEHS, P.O. Box 12233, Mail Stop: K2–
16, Research Triangle Park, NC, 27709,
(telephone) 919–541–2384, (fax) 919–
541–0947, (e-mail)
niceatm@niehs.nih.gov. Courier address:
NICEATM, NIEHS, Room 2034, 530
Davis Drive, Morrisville, NC 27560.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\10MYN1.SGM
10MYN1
Federal Register / Vol. 75, No. 89 / Monday, May 10, 2010 / Notices
jlentini on DSKJ8SOYB1PROD with NOTICES
Background
ICCVAM originally recommended the
LLNA as a valid stand-alone alternative
method to existing ACD test methods in
1999 (NIH publication No. 99–4494;
available at https://iccvam.niehs.nih.gov/
docs/immunotox_docs/llna/
llnarep.pdf). ICCVAM recommended
that the LLNA could be used as a
substitute for the existing guinea pig
based test methods for most testing
situations, which would reduce the
number of animals required and avoid
pain and distress. The Environmental
Protection Agency (EPA), the Food and
Drug Administration (FDA), and the
Consumer Product Safety Commission
(CPSC) subsequently accepted the
method as a valid substitute. The
Organization for Economic Co-operation
and Development (OECD) adopted the
LLNA as international OECD Test
Guideline 429 and the International
Standards Organization (ISO) adopted
the LLNA as ISO Test 10993–10.
The updated LLNA test method
protocol uses 20% fewer animals than
the original LLNA protocol
recommended by ICCVAM in 1999, and
provides improved guidance on dose
selection and other procedures to
improve assay accuracy and
reproducibility. The rLLNA procedure
can further reduce the number of
animals required by 40% compared to
the updated LLNA protocol multi-dose
procedure. ICCVAM recommends that
the rLLNA test method should be
routinely considered before conducting
the traditional multi-dose LLNA, and
should be used as the initial test for
ACD where determined appropriate.
ICCVAM evaluation and complete
recommendations for the updated LLNA
test method protocol and the rLLNA
procedure are provided in the ICCVAM
Test Method Evaluation Report: The
Reduced Murine Local Lymph Node
Assay: An Alternative Test Method
Using Fewer Animals to Assess the
Allergic Contact Dermatitis Potential of
Chemicals and Products (NIH
Publication No. 09–6439, available at
https://iccvam.niehs.nih.gov/methods/
immunotox/LLNA–LD/TMER.htm).
ICCVAM also recommends that the
LLNA test method performance
standards can be used to efficiently
evaluate the validity of modified test
methods that are mechanistically and
functionally similar to the traditional
LLNA. The LLNA test method
performance standards are provided in
the ICCVAM report, Recommended
Performance Standards: Murine Local
Lymph Node Assay (NIH Publication
No. 09–7357, available at https://
VerDate Mar<15>2010
17:18 May 07, 2010
Jkt 220001
iccvam.niehs.nih.gov/methods/
immunotox/PerfStds/llna-ps.htm).
ICCVAM evaluated the updated
versions of the LLNA in response to a
2007 nomination from the CPSC
(https://iccvam.niehs.nih.gov/methods/
immunotox/llnadocs/
CPSC_LLNA_nom.pdf). The nomination
also requested that ICCVAM evaluate
the validation status of (1) new versions
of the LLNA test method protocol that
do not require the use of radioactive
materials; (2) use of the LLNA to test
mixtures, aqueous solutions, metals,
and other substances; and (3) use of the
LLNA to determine ACD potency
categories for hazard classification and
labeling purposes. ICCVAM
recommendations on these new versions
and applications are undergoing
finalization and will be forwarded to
Federal agencies in 2010.
Agency Reponses to ICCVAM
Recommendations
In September 2009, ICCVAM
forwarded final test method
recommendations for the rLLNA, the
updated LLNA test method protocol,
and LLNA performance standards to
U.S. Federal agencies for consideration,
in accordance with the ICCVAM
Authorization Act of 2000 (42 U.S.C.
285l–3(e)(4)) (74 FR 50212). The
ICCVAM Authorization Act requires
member agencies to review ICCVAM
test method recommendations and
notify ICCVAM in writing of their
findings no later than 180 days after
receipt of recommendations. The Act
also requires ICCVAM to make ICCVAM
recommendations and agency responses
available to the public. Agency
responses are to include identification
of relevant test methods for which the
ICCVAM test method recommendations
may be added or substituted, and
indicate any revisions or planned
revisions to existing guidelines,
guidances, or regulations to be made in
response to these recommendations.
Background Information on ICCVAM
and NICEATM
ICCVAM is an interagency committee
composed of representatives from 15
Federal regulatory and research agencies
that use, generate, or disseminate
toxicological information. ICCVAM
conducts technical evaluations of new,
revised, and alternative methods with
regulatory applicability and promotes
the scientific validation and regulatory
acceptance of toxicological test methods
that more accurately assess the safety
and hazards of chemicals and products
and that refine, reduce, and replace
animal use. The ICCVAM Authorization
Act of 2000 established ICCVAM as a
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
25867
permanent interagency committee of the
NIEHS under NICEATM. NICEATM
administers ICCVAM and provides
scientific and operational support for
ICCVAM-related activities. NICEATM
and ICCVAM work collaboratively to
evaluate new and improved test
methods applicable to the needs of U.S.
Federal agencies. Additional
information about ICCVAM and
NICEATM can be found on their Web
site (https://www.iccvam.niehs.nih.gov).
Dated: April 30, 2010.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2010–10954 Filed 5–7–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Toxicology Program (NTP)
Interagency Center for the Evaluation
of Alternative Toxicological Methods
(NICEATM): International Workshop on
Alternative Methods To Reduce,
Refine, and Replace the Use of
Animals in Vaccine Potency and Safety
Testing: State of the Science and
Future Directions
AGENCY: National Institute of
Environmental Health Sciences
(NIEHS), National Institutes of Health
(NIH), Department of Health and Human
Services.
ACTION: Announcement of a workshop.
SUMMARY: The Interagency Coordinating
Committee on the Validation of
Alternative Methods (ICCVAM) and
NICEATM announce an upcoming
‘‘International Workshop on Alternative
Methods to Reduce, Refine, and Replace
the Use of Animals in Vaccine Potency
and Safety Testing: State of the Science
and Future Directions.’’ The workshop
will bring together an international
group of scientific experts from
government, industry, and academia to
review the current state of the science,
availability, and future need for
alternative methods that can reduce,
refine, and replace the use of animals
for human and veterinary vaccine postlicensing potency and safety testing.
Plenary and breakout sessions will
address current U.S. and international
regulatory requirements, currently
available alternatives, and future
research, development, and validation
activities needed to further advance the
use of alternative methods for vaccine
post-licensing potency and safety
testing. This workshop is free and open
E:\FR\FM\10MYN1.SGM
10MYN1
Agencies
[Federal Register Volume 75, Number 89 (Monday, May 10, 2010)]
[Notices]
[Pages 25866-25867]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-10954]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Toxicology Program (NTP); NTP Interagency Center for the
Evaluation of Alternative Toxicological Methods (NICEATM); Federal
Agency Responses to Interagency Coordinating Committee on the
Validation of Alternative Methods Recommendations on the Murine Local
Lymph Node Assay, An Alternative Test Method for Assessing the Allergic
Contact Dermatitis Potential of Chemicals and Products: Notice of
Availability
AGENCY: National Institute of Environmental Health Sciences (NIEHS),
National Institutes of Health (NIH).
ACTION: Notice of Availability.
-----------------------------------------------------------------------
SUMMARY: U.S. Federal agency responses to Interagency Coordinating
Committee on the Validation of Alternative Methods (ICCVAM) test method
recommendations on the murine local lymph node assay (LLNA), an
alternative safety testing method used to assess the potential of
chemicals and products to cause allergic contact dermatitis (ACD), are
now available. ICCVAM recommended an updated LLNA test method protocol,
a reduced LLNA procedure (rLLNA), and LLNA test method performance
standards. In accordance with the ICCVAM Authorization Act, ICCVAM
previously forwarded recommendations to Federal agencies and made these
recommendations available to the public (74 FR 50212). Agencies have
now notified ICCVAM in writing of their findings and ICCVAM is making
these responses available to the public. Federal agency responses are
available on the NICEATM-ICCVAM Web site at https://iccvam.niehs.nih.gov/methods/immunotox/rLLNA.htm and https://iccvam.niehs.nih.gov/methods/immunotox/llna_PerfStds.htm. The ICCVAM
recommendations are provided in ICCVAM Test Method Evaluation Reports,
which are available on the NICEATM-ICCVAM Web site at https://iccvam.niehs.nih.gov/methods/immunotox/LLNA-LD/TMER.htm and https://iccvam.niehs.nih.gov/methods/immunotox/PerfStds/llna-ps.htm.
FOR FURTHER INFORMATION CONTACT: Dr. William S. Stokes, Director,
NICEATM, NIEHS, P.O. Box 12233, Mail Stop: K2-16, Research Triangle
Park, NC, 27709, (telephone) 919-541-2384, (fax) 919-541-0947, (e-mail)
niceatm@niehs.nih.gov. Courier address: NICEATM, NIEHS, Room 2034, 530
Davis Drive, Morrisville, NC 27560.
SUPPLEMENTARY INFORMATION:
[[Page 25867]]
Background
ICCVAM originally recommended the LLNA as a valid stand-alone
alternative method to existing ACD test methods in 1999 (NIH
publication No. 99-4494; available at https://iccvam.niehs.nih.gov/docs/immunotox_docs/llna/llnarep.pdf). ICCVAM recommended that the LLNA
could be used as a substitute for the existing guinea pig based test
methods for most testing situations, which would reduce the number of
animals required and avoid pain and distress. The Environmental
Protection Agency (EPA), the Food and Drug Administration (FDA), and
the Consumer Product Safety Commission (CPSC) subsequently accepted the
method as a valid substitute. The Organization for Economic Co-
operation and Development (OECD) adopted the LLNA as international OECD
Test Guideline 429 and the International Standards Organization (ISO)
adopted the LLNA as ISO Test 10993-10.
The updated LLNA test method protocol uses 20% fewer animals than
the original LLNA protocol recommended by ICCVAM in 1999, and provides
improved guidance on dose selection and other procedures to improve
assay accuracy and reproducibility. The rLLNA procedure can further
reduce the number of animals required by 40% compared to the updated
LLNA protocol multi-dose procedure. ICCVAM recommends that the rLLNA
test method should be routinely considered before conducting the
traditional multi-dose LLNA, and should be used as the initial test for
ACD where determined appropriate. ICCVAM evaluation and complete
recommendations for the updated LLNA test method protocol and the rLLNA
procedure are provided in the ICCVAM Test Method Evaluation Report: The
Reduced Murine Local Lymph Node Assay: An Alternative Test Method Using
Fewer Animals to Assess the Allergic Contact Dermatitis Potential of
Chemicals and Products (NIH Publication No. 09-6439, available at
https://iccvam.niehs.nih.gov/methods/immunotox/LLNA-LD/TMER.htm).
ICCVAM also recommends that the LLNA test method performance
standards can be used to efficiently evaluate the validity of modified
test methods that are mechanistically and functionally similar to the
traditional LLNA. The LLNA test method performance standards are
provided in the ICCVAM report, Recommended Performance Standards:
Murine Local Lymph Node Assay (NIH Publication No. 09-7357, available
at https://iccvam.niehs.nih.gov/methods/immunotox/PerfStds/llna-ps.htm).
ICCVAM evaluated the updated versions of the LLNA in response to a
2007 nomination from the CPSC (https://iccvam.niehs.nih.gov/methods/immunotox/llnadocs/CPSC_LLNA_nom.pdf). The nomination also requested
that ICCVAM evaluate the validation status of (1) new versions of the
LLNA test method protocol that do not require the use of radioactive
materials; (2) use of the LLNA to test mixtures, aqueous solutions,
metals, and other substances; and (3) use of the LLNA to determine ACD
potency categories for hazard classification and labeling purposes.
ICCVAM recommendations on these new versions and applications are
undergoing finalization and will be forwarded to Federal agencies in
2010.
Agency Reponses to ICCVAM Recommendations
In September 2009, ICCVAM forwarded final test method
recommendations for the rLLNA, the updated LLNA test method protocol,
and LLNA performance standards to U.S. Federal agencies for
consideration, in accordance with the ICCVAM Authorization Act of 2000
(42 U.S.C. 285l-3(e)(4)) (74 FR 50212). The ICCVAM Authorization Act
requires member agencies to review ICCVAM test method recommendations
and notify ICCVAM in writing of their findings no later than 180 days
after receipt of recommendations. The Act also requires ICCVAM to make
ICCVAM recommendations and agency responses available to the public.
Agency responses are to include identification of relevant test methods
for which the ICCVAM test method recommendations may be added or
substituted, and indicate any revisions or planned revisions to
existing guidelines, guidances, or regulations to be made in response
to these recommendations.
Background Information on ICCVAM and NICEATM
ICCVAM is an interagency committee composed of representatives from
15 Federal regulatory and research agencies that use, generate, or
disseminate toxicological information. ICCVAM conducts technical
evaluations of new, revised, and alternative methods with regulatory
applicability and promotes the scientific validation and regulatory
acceptance of toxicological test methods that more accurately assess
the safety and hazards of chemicals and products and that refine,
reduce, and replace animal use. The ICCVAM Authorization Act of 2000
established ICCVAM as a permanent interagency committee of the NIEHS
under NICEATM. NICEATM administers ICCVAM and provides scientific and
operational support for ICCVAM-related activities. NICEATM and ICCVAM
work collaboratively to evaluate new and improved test methods
applicable to the needs of U.S. Federal agencies. Additional
information about ICCVAM and NICEATM can be found on their Web site
(https://www.iccvam.niehs.nih.gov).
Dated: April 30, 2010.
John R. Bucher,
Associate Director, National Toxicology Program.
[FR Doc. 2010-10954 Filed 5-7-10; 8:45 am]
BILLING CODE 4140-01-P